| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
132 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
-13 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Insite Vision Inc. was a pharmaceutical company based in Alameda, California. It focused on the development and commercialization of ophthalmic products to treat various eye diseases and conditions.
The company's primary focus was on developing innovative therapies for diseases such as dry eye syndrome, blepharitis, and conjunctivitis. Insite Vision Inc. developed a range of products including eye drops, ointments, and gels, which aimed to alleviate symptoms and improve patients' quality of life.
Insite Vision Inc. also had a strong research and development program dedicated to discovering and advancing novel drug candidates. The company utilized advanced technologies and collaborations with research institutions to identify potential therapeutic targets and develop new treatment options for eye diseases.
In 2016, Insite Vision Inc. was acquired by Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company. The acquisition aimed to leverage Insite Vision's expertise in ophthalmic pharmaceuticals and strengthen Sun Pharmaceutical's presence in the eye care market.
Overall, Insite Vision Inc. was a pharmaceutical company that focused on the development and commercialization of ophthalmic products to address various eye diseases and conditions, before being acquired by Sun Pharmaceutical Industries Ltd.
|
%